GREEN BROOK, NJ, December 10, 2020 /24-7PressRelease/ -- Gianluca Pirozzi, MD, PhD, has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Dr. Pirozzi received a Doctorate of Medicine from Università Campus Bio-Medico di Roma in Italy, a Doctorate of Philosophy in Immunology from Sapienza Università di Roma in Italy, a Post-Doctorate degree in Immunology from the Institut Pasteur in Paris, France, and business training at the London Business School, UK.
Dr. Pirozzi began his career as a Medical Advisor for Servier in Italy in 2001. Spending several years with Sanofi in Paris, France as a Global safety officer, he then relocated to New Jersey, USA to work in Early and Late Stage Clinical Development in Immunology, when he became the Global Project Head of Dupixent, a medicine that has revolutionized the field of allergic and atopic diseases. Dr Pirozzi subsequently was inspired to pursue a career in rare diseases after his daughter Valentina was diagnosed with a rare chromosomal syndrome, called Smith-Magenis Syndrome. He became Head of Development for Rare Diseases and Gene Therapy in Sanofi-Genzyme's office in Cambridge, Massachusetts. After nearly two decades in his field, Dr. Pirozzi now serves as Senior Vice President, Head of Clinical Development and Translational Sciences at Alexion Pharmaceuticals, Inc., positions he assumed in 2020. At Alexion, he is responsible for the development of medicines for rare and devastating diseases in hematology, nephrology, neurology, ophthalmology, and for metabolic syndromes.
In addition to his primary roles, Dr. Pirozzi served as a board member of Imbria Pharmaceuticals from September 2008 to May 2020, and is on the board of directors of Timber Pharmaceutical since June 2020, where he helps drive the mission of the company to develop medication for rare dermatologic conditions. He is scientific advisor for the Smith-Magenis Syndrome Research Foundation, a 501(c)3 nonprofit organization founded in 2010 to raise awareness for Smith-Magenis Syndrome, a complex developmental disorder characterized by a pattern of congenital abnormalities. For more information, visit https://www.smsresearchfoundation.org.
As a respected voice in his field, Dr. Pirozzi has published approximately 50 publications primarily in the field of Immunology and Immune-mediated diseases. He speaks fluently Italian, English, French and Spanish. Looking toward the future, Dr. Pirozzi plans to continue on his mission to translate breakthrough sciences in into innovative solutions by developing life-transforming medicines with urgency and agility for patients and their families.
About Marquis Who's Who®
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® now publishes many Who's Who titles, including Who's Who in America®, Who's Who in the World®, Who's Who in American Law®, Who's Who in Medicine and Healthcare®, Who's Who in Science and Engineering®, and Who's Who in Asia®. Marquis® publications may be visited at the official Marquis Who's Who® website at www.marquiswhoswho.com.
# # #